Publisher
Springer Berlin Heidelberg
Reference133 articles.
1. Baldysiak-Figiel A, Lang GK, Kampmeier J, Lang GE (2004) Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. Journal of Endocrinology 180: 417–424
2. Bohm BO, Feldmann B, Lang GK, Lang GE (1999) Treatment of diabetic retinopathy with long-acting somatostatin analogues. In Octreotide: The next decade. Ed SWJ Lamberts BioScientifica Ltd, Bristol, pp241–257
3. Bohm BO, Lang GK, Jehle PM, Feldmann B, Lang GE (2001) Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-rsk proliferative diabetic retinopathy. Horm Metab Res 33: 300–306
4. Bohm BO, Lang GE, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, Bouck N (2003) Low content of the natural ocular antiangiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologica 46:394–400
5. Chantelau E, Frystyk J (2005) Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration – a case report. Growth Horm IGF Res 15:130–135